Search Results
Diabetes Institute, Ohio University, Athens, Ohio, USA
Department of Biological Sciences, Ohio University, Athens, Ohio, USA
Molecular & Cellular Biology Program, College of Arts and Sciences, Ohio University, Athens, Ohio, USA
Search for other papers by Ashley Patton in
Google Scholar
PubMed
Diabetes Institute, Ohio University, Athens, Ohio, USA
Search for other papers by Tyler Church in
Google Scholar
PubMed
Search for other papers by Caroline Wilson in
Google Scholar
PubMed
Diabetes Institute, Ohio University, Athens, Ohio, USA
Search for other papers by Jean Thuma in
Google Scholar
PubMed
Molecular & Cellular Biology Program, College of Arts and Sciences, Ohio University, Athens, Ohio, USA
Biomedical Engineering Program, Ohio University, Athens, Ohio, USA
Search for other papers by Douglas J Goetz in
Google Scholar
PubMed
Department of Biomedical Sciences, Ohio University, Athens, Ohio, USA
The Edison Biotechnology Institute, Ohio University, Athens, Ohio, USA
Search for other papers by Darlene E Berryman in
Google Scholar
PubMed
Diabetes Institute, Ohio University, Athens, Ohio, USA
The Edison Biotechnology Institute, Ohio University, Athens, Ohio, USA
Search for other papers by Edward O List in
Google Scholar
PubMed
Diabetes Institute, Ohio University, Athens, Ohio, USA
Search for other papers by Frank Schwartz in
Google Scholar
PubMed
Diabetes Institute, Ohio University, Athens, Ohio, USA
Department of Biological Sciences, Ohio University, Athens, Ohio, USA
Molecular & Cellular Biology Program, College of Arts and Sciences, Ohio University, Athens, Ohio, USA
Biomedical Engineering Program, Ohio University, Athens, Ohio, USA
Department of Biomedical Sciences, Ohio University, Athens, Ohio, USA
Search for other papers by Kelly D McCall in
Google Scholar
PubMed
Introduction Obesity is the single most important risk factor for the development of nonalcoholic fatty liver disease (NAFLD), which is the most prevalent liver disease in the western hemisphere ( Lazo & Clark 2008 , Bellentani et al . 2010
Search for other papers by Rodrigo Martins Pereira in
Google Scholar
PubMed
Search for other papers by Kellen Cristina da Cruz Rodrigues in
Google Scholar
PubMed
Search for other papers by Chadi Pellegrini Anaruma in
Google Scholar
PubMed
Search for other papers by Marcella Ramos Sant’Ana in
Google Scholar
PubMed
Search for other papers by Thaís Dantis Pereira de Campos in
Google Scholar
PubMed
Search for other papers by Rodrigo Stellzer Gaspar in
Google Scholar
PubMed
Search for other papers by Raphael dos Santos Canciglieri in
Google Scholar
PubMed
Search for other papers by Diego Gomes de Melo in
Google Scholar
PubMed
Department of Social and Administrative Sciences, School of Pharmacy, MCPHS University, Boston, Massachusetts, USA
Search for other papers by Rania A Mekary in
Google Scholar
PubMed
Postgraduate Program in Rehabilitation and Functional Performance, Ribeirão Preto Medical School, USP, Ribeirão Preto, São Paulo, Brazil
Search for other papers by Adelino Sanchez Ramos da Silva in
Google Scholar
PubMed
Search for other papers by Dennys Esper Cintra in
Google Scholar
PubMed
Search for other papers by Eduardo Rochete Ropelle in
Google Scholar
PubMed
Search for other papers by José Rodrigo Pauli in
Google Scholar
PubMed
Search for other papers by Leandro Pereira de Moura in
Google Scholar
PubMed
Introduction Nonalcoholic fatty liver disease (NAFLD) is a pre-condition for most common liver diseases, and it can be developed from hepatic steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis, to hepatocellular carcinoma (HCC) ( Tilg
Search for other papers by Lei Yu in
Google Scholar
PubMed
Search for other papers by Haoran Wang in
Google Scholar
PubMed
Search for other papers by Xiaoxue Han in
Google Scholar
PubMed
Search for other papers by Honghui Liu in
Google Scholar
PubMed
Search for other papers by Dalong Zhu in
Google Scholar
PubMed
Search for other papers by Wenhuan Feng in
Google Scholar
PubMed
Search for other papers by Jinhui Wu in
Google Scholar
PubMed
Search for other papers by Yan Bi in
Google Scholar
PubMed
Introduction Non-alcoholic fatty liver disease (NAFLD), a major epidemic chronic liver disease worldwide, is often accompanied by systemic metabolic disorders, such as obesity, type 2 diabetes and cardiovascular diseases ( Byrne & Targher 2015
Search for other papers by Guangcui Xu in
Google Scholar
PubMed
Search for other papers by Tingting Yan in
Google Scholar
PubMed
Search for other papers by Qiang Peng in
Google Scholar
PubMed
Search for other papers by Haibin Li in
Google Scholar
PubMed
Search for other papers by Weidong Wu in
Google Scholar
PubMed
Search for other papers by Xianwen Yi in
Google Scholar
PubMed
Search for other papers by Yingzheng Zhao in
Google Scholar
PubMed
Introduction In association with the obesity pandemic, the prevalence of nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis ( Sanyal et al . 2010 ), is rising in the whole world and is estimated to
Search for other papers by Gabriel Forn-Cuní in
Google Scholar
PubMed
Search for other papers by Monica Varela in
Google Scholar
PubMed
Search for other papers by Conrado M Fernández-Rodríguez in
Google Scholar
PubMed
Search for other papers by Antonio Figueras in
Google Scholar
PubMed
Search for other papers by Beatriz Novoa in
Google Scholar
PubMed
diseases are part of a condition termed metabolic syndrome. The hepatic component of metabolic syndrome is non-alcoholic fatty liver disease (NAFLD). This term comprises a wide range of progressive liver injuries including bland steatosis, variable degrees
Search for other papers by Ya Liu in
Google Scholar
PubMed
Search for other papers by Xiaoqing Zhou in
Google Scholar
PubMed
Search for other papers by Ye Xiao in
Google Scholar
PubMed
Search for other papers by Changjun Li in
Google Scholar
PubMed
Search for other papers by Yan Huang in
Google Scholar
PubMed
Search for other papers by Qi Guo in
Google Scholar
PubMed
Search for other papers by Tian Su in
Google Scholar
PubMed
Search for other papers by Lei Fu in
Google Scholar
PubMed
Search for other papers by Liping Luo in
Google Scholar
PubMed
Introduction Nonalcoholic fatty liver disease (NAFLD), characterized mainly by hepatic steatosis, is the most common liver disease worldwide ( Birkenfeld & Shulman 2014 , Meex & Watt 2017 ). It is reported that NAFLD is closely associated
Search for other papers by Lise Margrethe Sjøgaard-Frich in
Google Scholar
PubMed
Search for other papers by Morten Sølling Henriksen in
Google Scholar
PubMed
Search for other papers by Shi Min Lam in
Google Scholar
PubMed
Search for other papers by Frida Jolande Birkbak in
Google Scholar
PubMed
Search for other papers by Dominika Czaplinska in
Google Scholar
PubMed
Search for other papers by Mette Flinck in
Google Scholar
PubMed
Search for other papers by Stine F. Pedersen in
Google Scholar
PubMed
Non-alcoholic fatty liver disease (NAFLD) is the fastest growing cause of liver-associated death globally. Whole-body knockout (KO) of Na+/H+ exchanger 1 (NHE1, SLC9A1) was previously proposed to protect against high fat diet-induced liver damage, however, mechanistic insight was lacking. The aim of the present work was to address this question in vitro to determine how NHE1 specifically in hepatocytes impacts lipid overload-induced inflammation, fibrosis, and hepatocyte- hepatic stellate cell (HSC) crosstalk. We induced palmitate (PA)-based steatosis in AML12 and HepG2 hepatocytes, manipulated NHE1 activity pharmacologically and by CRISPR-Cas knockout (KO) and -overexpression, and measured intracellular pH (pHi), steatosis-associated inflammatory and fibrotic mediators and cell death. PA treatment increased NHE1 mRNA levels but modestly reduced NHE1 protein expression and hepatocyte pHi. NHE1 KO in hepatocytes did not alter lipid droplet accumulation but reduced inflammatory signaling (p38 MAPK activity), lipotoxicity (4-HNE accumulation) and apoptosis (PARP cleavage). Conditioned medium from PA-treated hepatocytes increased expression of NHE1 and of the fibrosis regulator tissue inhibitor of matrix metalloproteases-2 (TIMP2) in LX-2 HSCs, in a manner abolished by NHE1 KO in hepatocytes. We conclude that NHE1 is regulated in NAFLD in vitro and contributes to the ensuing damage by aggravating hepatocyte injury and stimulating hepatocyte-HSC crosstalk.
Search for other papers by Christopher M Mulligan in
Google Scholar
PubMed
Search for other papers by Jacob E Friedman in
Google Scholar
PubMed
properly. Depending on the health of the mother, maternal microbe communities may already be imbalanced when passed on to the infant. In children, metabolic diseases, including obesity, insulin resistance and nonalcoholic fatty liver disease (NAFLD), along
Search for other papers by João Paulo G Camporez in
Google Scholar
PubMed
Search for other papers by Mohamed Asrih in
Google Scholar
PubMed
Department of Internal Medicine, Howard Hughes Medical Institute, Service of Endocrinology, Yale University School of Medicine, New Haven, Connecticut 06536, USA
Search for other papers by Dongyan Zhang in
Google Scholar
PubMed
Department of Internal Medicine, Howard Hughes Medical Institute, Service of Endocrinology, Yale University School of Medicine, New Haven, Connecticut 06536, USA
Search for other papers by Mario Kahn in
Google Scholar
PubMed
Search for other papers by Varman T Samuel in
Google Scholar
PubMed
Department of Internal Medicine, Howard Hughes Medical Institute, Service of Endocrinology, Yale University School of Medicine, New Haven, Connecticut 06536, USA
Search for other papers by Michael J Jurczak in
Google Scholar
PubMed
Department of Internal Medicine, Howard Hughes Medical Institute, Service of Endocrinology, Yale University School of Medicine, New Haven, Connecticut 06536, USA
Search for other papers by François R Jornayvaz in
Google Scholar
PubMed
(NHANES), it is estimated that more than 34% of adults are obese and 68% are overweight or obese ( Flegal et al . 2010 ). In parallel with obesity, nonalcoholic fatty liver disease (NAFLD), which is now the most prevalent chronic liver disease in the USA
Search for other papers by Qiong Lv in
Google Scholar
PubMed
Laboratory of Lipids and Glucose Metabolism, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Search for other papers by Rufei Gao in
Google Scholar
PubMed
Search for other papers by Chuan Peng in
Google Scholar
PubMed
Search for other papers by Juan Yi in
Google Scholar
PubMed
Search for other papers by Lulu Liu in
Google Scholar
PubMed
Search for other papers by Shumin Yang in
Google Scholar
PubMed
Search for other papers by Danting Li in
Google Scholar
PubMed
Search for other papers by Jinbo Hu in
Google Scholar
PubMed
Search for other papers by Ting Luo in
Google Scholar
PubMed
Search for other papers by Mei Mei in
Google Scholar
PubMed
Search for other papers by Ying Song in
Google Scholar
PubMed
Search for other papers by Chaodong Wu in
Google Scholar
PubMed
Search for other papers by Xiaoqiu Xiao in
Google Scholar
PubMed
Search for other papers by Qifu Li in
Google Scholar
PubMed
Introduction Excess hepatic deposition of lipids, especially triglyceride (TG), is one of the important features of nonalcoholic fatty liver disease (NAFLD). Over-nutrition, metabolic diseases and genetic factors were widely considered to